Sign inJoin waitlistJoin the waitlist

Alaina Brown

Program Director, Gynecologic Oncology Fellowship · Vanderbilt University Medical Center

Credentials: · · · · · ·

History

Gynecologic Oncology Fellowship · Vanderbilt University Medical Center
Present
Vanderbilt University Medical Center
Present

Gynecologic Oncology
University of Texas M D Anderson Cancer Center
2013–2016
Obstetrics and Gynecology
Johns Hopkins Hospital and Health System
2008–2012
University of Texas at Houston
McGovern Medical School at The University of Texas Health Science Center at Houston
2004–2008

Research

Association of Preoperative Patient Frailty and Operative Stress With Postoperative Mortality
JAMA Surgery · 2020 · 327 citations
Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database
Gynecologic Oncology · 2015 · 62 citations
Does death anxiety affect end-of-life care discussions?
International Journal of Gynecological Cancer · 2014 · First of 6 authors · 49 citations

Lauren Prescott
21 papers · 6 as a fellow
Diane Bodurka
13 papers
Lois Ramondetta
13 papers
Jolyn Taylor
6 papers · 6 as a resident
Marta Crispens
5 papers
Premal Thaker
5 papers
CL
Charles Levenback
4 papers
Michael Frumovitz
4 papers
Myrick Shinall
4 papers
Kathleen Schmeler
3 papers
LB
Lia Bos
3 papers · 3 as a resident
Mohana Karlekar
3 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2021–2026